Ophthotech's anti-PDGF boosts Lucentis: will Genentech or Regeneron acquire?
This article was originally published in Scrip
Executive Summary
The US private company Ophthotech has released Phase IIb data showing that a combination of its drug candidate Fovista and Roche/Genentech's Lucentis (ranibizumab) worked much better in improving vision – a 62% imporovement, according to Ophthotech - in wet age-related macular degeneration than Lucentis alone.